Human induced pluripotent stem cell-derived cardiac progenitor cells in phenotypic screening: A transforming growth factor-β type 1 receptor kinase inhibitor induces efficient cardiac differentiation

Stem Cells Translational Medicine

Volumn 5, Issue 2, 2016, Pages 164-174

  Drowley, Lauren ^a   Koonce, Chad ^b   Peel, Samantha ^c   Jonebring, Anna ^d   Plowright, Alleyn T ^a   Kattman, Steven J ^b   Andersson, Henrik ^d   Anson, Blake ^b   Swanson, Bradley J ^b   Wang, Qing Dong ^a   Brolen, Gabriella ^d  

^a Cardiovascular and Gastrointestinal IMed   (Sweden)

^b Cellular Dynamics International   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Assay development; Differentiation; Drug discovery; High throughput screening; Phenotypic screening; Proliferation; Stem cells

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; HOMEOBOX PROTEIN NKX-2.5; HOMEODOMAIN PROTEIN; MOLECULAR LIBRARY; NKX2-5 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CARDIAC STEM CELL; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CRYOPRESERVATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEART DEVELOPMENT; HUMAN; HUMAN CELL; PHENOTYPE; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CHEMISTRY; CYTOLOGY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SCREENING; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PLASMID; PRIMARY CELL CULTURE;

BIOMARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HOMEOBOX PROTEIN NKX-2.5; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; PHENOTYPE; PLASMIDS; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84969427414     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0114     Document Type: Article

References (42)

1. Karsner HT, Saphir O, Todd TW. The state of the cardiac muscle in hypertrophy and atrophy. Am J Pathol 1925;1:351-372.1.
2. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
3. Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004; 95:911-921.
4. Itzhaki-Alfia A, Leor J, Raanani E et al. Patient characteristics and cell source determine the number of isolated human cardiac progenitor cells. Circulation 2009;120:2559-2566.
5. van Vliet P, Smits AM, de Boer TP et al. Foetal and adult cardiomyocyte progenitor cells have different developmental potential. J Cell Mol Med 2010;14:861-870.
6. Emmert MY, Emmert LS, Martens A et al. Higher frequencies of BCRP+ cardiac resident cells in ischaemic human myocardium. Eur Heart J 2013;34:2830-2838.
7. Guan K, Hasenfuss G. Cardiac resident progenitor cells: Evidence and functional significance. Eur Heart J 2013;34:2784-2787.
8. Malliaras K, Ibrahim A, Tseliou E et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol Med 2014;6:760-777.
9. Hsueh YC, Wu JM, Yu CK et al. Prostaglandin E₂ promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol Med 2014;6:496-503.
10. van Vliet P, Roccio M, Smits AM et al. Progenitor cells isolated from the human heart: A potential cell source for regenerative therapy. Neth Heart J 2008;16:163-169.
11. van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. Nat Med 2014;20:1386-1393.
12. Nsair A, Schenke-Layland K, Van Handel B et al. Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells. PLoS One 2012;7:e45603.
13. Skelton RJ, Costa M, Anderson DJ et al. SIRPA, VCAM1 and CD34 identify discrete lineages during early human cardiovascular development. Stem Cell Res (Amst) 2014;13:172-179.
14. Kattman SJ, Witty AD, Gagliardi M et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011;8:228-240.
15. Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008;453:524-528.
16. Chong JJ, Forte E, Harvey RP. Developmental origins and lineage descendants of endogenous adult cardiac progenitor cells. Stem Cell Res (Amst) 2014;13(Pt B):592-614.
17. Chen WP, Wu SM. Small molecule regulators of postnatal Nkx2.5 cardiomyoblast proliferation and differentiation. J Cell Mol Med 2012;16:961-965.
18. Koudstaal S, Jansen O, Lorkeers SJ et al. Concise review: Heart regeneration and the role of cardiac stem cells 2013;2:434-443.
19. Eggert US. The why and how of phenotypic small-molecule screens. Nat Chem Biol 2013;9:206-209.
20. Engle SJ, Vincent F. Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J Biol Chem 2014;289:4562-4570.
21. Carlson C, Koonce C, Aoyama N et al. Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J Biomol Screen 2013;18:1203-1211.
22. Bunnage ME, Chekler EL, Jones LH. Target validation using chemical probes. Nat Chem Biol 2013;9:195-199.
23. Willems E, Spiering S, Davidovics H et al. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ Res 2011;109:360-364.
24. Plowright AT, Engkvist O, Gill A et al. Heart regeneration: Opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. Angew Chem Int Ed Engl 2014;53:4056-4075.
25. Mack AA, Kroboth S, Rajesh D et al. Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors. PLoS One 2011;6:e27956.
26. Ma J, Guo L, Fiene SJ et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011;301:H2006-H2017.
27. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell 2006;11:723-732.
28. Moretti A, Caron L, Nakano A et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006;127:1151-1165.
29. Wu SM, Fujiwara Y, Cibulsky SM et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell 2006;127:1137-1150.
30. Bondue A, Tännler S, Chiapparo G et al. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. J Cell Biol 2011;192: 751-765.
31. Molkentin JD, Lin Q, Duncan SA et al. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 1997;11:1061-1072.
32. Bu L, Jiang X, Martin-Puig S et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009;460:113-117.
33. Wang H, Hao J, Hong CC. Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/b-catenin signaling. ACS Chem Biol 2011;6:192-197.
34. Hughes JP, Rees S, Kalindjian SB et al. Principles of early drug discovery. Br J Pharmacol 2011;162:1239-1249.
35. Detillieux KA, Sheikh F, Kardami E et al. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003;57:8-19.
36. Minami I, Yamada K, Otsuji TG et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine-and xeno-free conditions. Cell Reports 2012;2:1448-1460.
37. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5: 100-107.
38. Gellibert F, Woolven J, Fouchet MH et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF- b type I receptor inhibitors. J Med Chem 2004;47:4494-4506.
39. Inman GJ, Nicolás FJ, Callahan JF et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
40. Grygielko ET, Martin WM, Tweed C et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005;313:943-951.
41. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132.
42. Willems E, Cabral-Teixeira J, Schade D et al. Small molecule-mediated TGF-b type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell 2012;11:242-252.